Literature DB >> 9029182

Predictors for optimal mobilization and subsequent engraftment of peripheral blood progenitor cells following intermediate dose cyclophosphamide and G-CSF.

J Morton1, A Morton, R Bird, C Hutchins, S Durrant.   

Abstract

Fifty consecutive patients undergoing cyclophosphamide/G-CSF mobilization were studied for indicators predictive for adequate harvest (CD34+ cells > 2 x 10(6)/kg, CFU-GM > 1 x 10(5)/kg). Target yields following a single leukopheresis were achieved for 66% of patients (89% with no previous alkylation chemotherapy or radiotherapy). Previous alkylation therapy, radiotherapy and low collection day platelet count were predictive of poor collection yields. Following reinfusion, the median time to platelets > 20 x 10(9)/l (PLT > 20) was 10 days and to neutrophils > 500 x 10(6)/l (ANC > 500) was 13 days. Total CD34+ cells infused was predictive of early platelet engraftment. Previous radiotherapy was inversely predictive of neutrophil engraftment. For the majority of patients not exposed to alkylation therapy or radiotherapy, adequate progenitor cells can be collected following a single leukopheresis. In patients suitable for future autologous bone marrow transplantation it would seem appropriate to avoid or minimize radiotherapy and alkylation therapy exposure in the pre-collection period.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9029182     DOI: 10.1016/s0145-2126(96)00059-8

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  3 in total

1.  Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma.

Authors:  Chitra Hosing; Rima M Saliba; Sheena Ahlawat; Martin Körbling; Partow Kebriaei; Amin Alousi; Marcos De Lima; Julia-Grace Okoroji; John McMannis; Muzaffar Qazilbash; Paolo Anderlini; Sergio Giralt; Richard E Champlin; Issa Khouri; Uday Popat
Journal:  Am J Hematol       Date:  2009-06       Impact factor: 10.047

2.  ESHAP and G-CSF is a superior blood stem cell mobilizing regimen compared to cyclophosphamide 1.5 g m(-2) and G-CSF for pre-treated lymphoma patients: a matched pairs analysis of 78 patients.

Authors:  M J Watts; S J Ings; D Leverett; A MacMillan; S Devereux; A H Goldstone; D C Linch
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

3.  Variant rs1801157 in the 3'UTR of SDF-1ß does not explain variability of healthy-donor G-CSF responsiveness.

Authors:  Miriam Schulz; Darja Karpova; Gabriele Spohn; Annette Damert; Erhard Seifried; Vera Binder; Halvard Bönig
Journal:  PLoS One       Date:  2015-03-24       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.